Contact
searchSearch
HMP Global

January 2011 - FRMC

Idelalisib Plus Rituximab to Treat CLL
01/21/2014
Tim Casey
New Orleans—Patients with heavily pretreated, relapsed chronic lymphocytic leukemia (CLL) not suitable for chemotherapy had a significant increase in progression-free survival, overall survival, and overall response rate if they received...
New Orleans—Patients with heavily pretreated, relapsed chronic lymphocytic leukemia (CLL) not suitable for chemotherapy had a significant increase in progression-free survival, overall survival, and overall response rate if they received...
New Orleans—Patients with...
01/21/2014
First Report Managed Care
Conference Insider
Benefits of a Utilization Management Program
01/22/2013
Tim Casey
Los Angeles—An analysis of commercially insured, non-Medicare members of Anthem Blue Cross and Blue Shield plans found that a utilization management program helped reduce the likelihood of follow-up visits for cardiac imaging by 11.7%, a...
Los Angeles—An analysis of commercially insured, non-Medicare members of Anthem Blue Cross and Blue Shield plans found that a utilization management program helped reduce the likelihood of follow-up visits for cardiac imaging by 11.7%, a...
Los Angeles—An analysis of...
01/22/2013
First Report Managed Care
News Connection
Smoking Cessation Training for Physicians Associated with Increased Counseling
01/17/2011
Tori Socha
Counseling by healthcare providers increases rates of smoking cessation rates, yet <50% of patients who smoke receive cessation counseling.
Counseling by healthcare providers increases rates of smoking cessation rates, yet <50% of patients who smoke receive cessation counseling.
Counseling by healthcare...
01/17/2011
First Report Managed Care
Feature
Reducing Polypharmacy in Community-Dwelling Elderly Patients
01/17/2011
Tori Socha
Compared with younger patients, elderly patients are most likely to have more comorbid conditions and are at risk for inappropriate medication use.
Compared with younger patients, elderly patients are most likely to have more comorbid conditions and are at risk for inappropriate medication use.
Compared with younger patients,...
01/17/2011
First Report Managed Care
Feature
Association of Avoidable Hospitalizations and Continuity of Care
01/17/2011
Tori Socha
Continuity of care (the relationship between physician and patient that goes beyond any specific disease or episode of illness) is a key feature of primary care. Studies have suggested that increased continuity of care may lead to improved...
Continuity of care (the relationship between physician and patient that goes beyond any specific disease or episode of illness) is a key feature of primary care. Studies have suggested that increased continuity of care may lead to improved...
Continuity of care (the...
01/17/2011
First Report Managed Care
Severe Hypoglycemia and Risk of Vascular Events
01/17/2011
Tori Socha
Excess mortality seen with intensive glucose control in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial has caused much speculation about the adverse effects of intensive glucose-lowering interventions in patients with...
Excess mortality seen with intensive glucose control in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial has caused much speculation about the adverse effects of intensive glucose-lowering interventions in patients with...
Excess mortality seen with...
01/17/2011
First Report Managed Care
Feature
Effect of Supplementation with Folic Acid to Lower Homocysteine Levels
01/17/2011
Tori Socha
Increased risk of cardiovascular disease (CVD), including coronary heart disease, stroke, and other occlusive vascular conditions, is known to be associated with elevated levels of plasma homocysteine. It is uncertain what effects...
Increased risk of cardiovascular disease (CVD), including coronary heart disease, stroke, and other occlusive vascular conditions, is known to be associated with elevated levels of plasma homocysteine. It is uncertain what effects...
Increased risk of cardiovascular...
01/17/2011
First Report Managed Care
Feature
Compatible but Nonidentical Plasma Transfusions Lead to Complications
01/17/2011
Mary Mihalovic
Trauma patients who received compatible, but not ABO-identical plasma transfusions experienced higher rates of overall complications, particularly sepsis and acute respiratory distress syndrome (ARDS), according to results of a recent study...
Trauma patients who received compatible, but not ABO-identical plasma transfusions experienced higher rates of overall complications, particularly sepsis and acute respiratory distress syndrome (ARDS), according to results of a recent study...
Trauma patients who received...
01/17/2011
First Report Managed Care
News Connection
Postoperative Hyperglycemia Important Risk Factor for SSI
01/17/2011
Kerri Fitzgerald
A recent study reported in the Archives of Surgery [2010;145(9):858-864] found that postoperative hyperglycemia is the most important independent risk factor for surgical site infection (SSI) in general surgery patients. Previous studies have...
A recent study reported in the Archives of Surgery [2010;145(9):858-864] found that postoperative hyperglycemia is the most important independent risk factor for surgical site infection (SSI) in general surgery patients. Previous studies have...
A recent study reported in the...
01/17/2011
First Report Managed Care
News Connection
Effect of Delaying Surgery on Outcomes in Adults with Acute Appendicitis
01/17/2011
Tori Socha
The most common emergent surgery performed worldwide is appendectomy; appendicitis accounts for approximately 1 million hospital stays each year. Recent advances in imaging and antibiosis have enabled improved preoperative assessment and...
The most common emergent surgery performed worldwide is appendectomy; appendicitis accounts for approximately 1 million hospital stays each year. Recent advances in imaging and antibiosis have enabled improved preoperative assessment and...
The most common emergent surgery...
01/17/2011
First Report Managed Care
Feature
Chemotherapy and Postoperative Complications in Women Undergoing Mastectomy and Immediate Breast Reconstruction
01/17/2011
Mary Beth Nierengarten
Results of a retrospective review [Arch Surg. 2010;145(9):880-885] indicate that complication rates after mastectomy and immediate breast reconstruction surgery are not significantly affected by inclusion of chemotherapy nor by timing of...
Results of a retrospective review [Arch Surg. 2010;145(9):880-885] indicate that complication rates after mastectomy and immediate breast reconstruction surgery are not significantly affected by inclusion of chemotherapy nor by timing of...
Results of a retrospective...
01/17/2011
First Report Managed Care
News Connection
End-of-Year Report on Public Opinion of Healthcare Reform
01/17/2011
The most recent Kaiser Family Foundation Health Tracking Poll has found that the public is still divided in their opinion of the healthcare reform law passed in March 2010. 
The most recent Kaiser Family Foundation Health Tracking Poll has found that the public is still divided in their opinion of the healthcare reform law passed in March 2010. 
The most recent Kaiser Family...
01/17/2011
First Report Managed Care
News Connection
Cost-Effectiveness and Impact of Lifestyle Intervention on Quality of Life
01/17/2011
Tori Socha
Compared with people who are physically active, people who lead sedentary lives are at a higher relative risk of mortality; unfit people have a higher risk than fit people. Lifestyle intervention programs aimed at increasing physical activity...
Compared with people who are physically active, people who lead sedentary lives are at a higher relative risk of mortality; unfit people have a higher risk than fit people. Lifestyle intervention programs aimed at increasing physical activity...
Compared with people who are...
01/17/2011
First Report Managed Care
News Connection
Costs and Resource Use at End of Life among Medicare Beneficiaries
01/17/2011
Tori Socha
Healthcare at the end of life is multifaceted, encompassing patient preferences and values, healthcare provider practices, and concerns about appropriate use of resources. The cost of end-of-life care is substantial, with more than one...
Healthcare at the end of life is multifaceted, encompassing patient preferences and values, healthcare provider practices, and concerns about appropriate use of resources. The cost of end-of-life care is substantial, with more than one...
Healthcare at the end of life is...
01/17/2011
First Report Managed Care
Feature
Chronic Opioid Therapy and Utilization of Emergency Departments
01/17/2011
Tori Socha
Chronic opioid therapy (COT) is an often-employed strategy for managing noncancer chronic pain. Along with the increase in COT for noncancer chronic pain has come an increase in reported opioid abuse and deaths from prescription opioid...
Chronic opioid therapy (COT) is an often-employed strategy for managing noncancer chronic pain. Along with the increase in COT for noncancer chronic pain has come an increase in reported opioid abuse and deaths from prescription opioid...
Chronic opioid therapy (COT) is...
01/17/2011
First Report Managed Care
News Connection
Severe Sepsis and Cognitive Impairment and Functional Disability
01/17/2011
Tori Socha
Cognitive and physical impairment have a major impact on caregiving needs and on healthcare costs to society.
Cognitive and physical impairment have a major impact on caregiving needs and on healthcare costs to society.
Cognitive and physical...
01/17/2011
First Report Managed Care
News Connection
Gemcitabine or Fluorouracil plus Folinic Acid for Pancreatic Cancer
01/17/2011
Tim Casey
In an open-label, phase 3, randomized controlled trial of patients with completely resected pancreatic cancer, researchers found that using gemcitabine did not result in improved overall survival when compared with using fluorouracil plus...
In an open-label, phase 3, randomized controlled trial of patients with completely resected pancreatic cancer, researchers found that using gemcitabine did not result in improved overall survival when compared with using fluorouracil plus...
In an open-label, phase 3,...
01/17/2011
First Report Managed Care
News Connection
Unplanned ED Visits and Hospitalizations Related to Outpatient Endoscopy
01/17/2011
Tori Socha
Gastrointestinal (GI) endoscopic procedures are performed at a rate of 15 million to 20 million per year in the United States. However, comprehensive data on the safety and complications from the procedure are limited; studies have utilized...
Gastrointestinal (GI) endoscopic procedures are performed at a rate of 15 million to 20 million per year in the United States. However, comprehensive data on the safety and complications from the procedure are limited; studies have utilized...
Gastrointestinal (GI) endoscopic...
01/17/2011
First Report Managed Care
News Connection
Intensive Blood Pressure Control in Patients with Hypertensive Chronic Kidney Disease
01/17/2011
Tori Socha
The prevalence of chronic kidney disease in adults in the United States increased from 10% for the period 1988-1994 to 13% for the period 1999-2004.
The prevalence of chronic kidney disease in adults in the United States increased from 10% for the period 1988-1994 to 13% for the period 1999-2004.
The prevalence of chronic kidney...
01/17/2011
First Report Managed Care
Feature
A Large-Scale Genomewide Association Study of Asthma
01/17/2011
Tori Socha
Asthma is a disease with a high prevalence and a chronic relapsing course. There are therapies available to treat mild asthma, but severe asthma remains difficult to treat. The societal cost of the disease is substantial, including direct...
Asthma is a disease with a high prevalence and a chronic relapsing course. There are therapies available to treat mild asthma, but severe asthma remains difficult to treat. The societal cost of the disease is substantial, including direct...
Asthma is a disease with a high...
01/17/2011
First Report Managed Care
News Connection
Association of Reduced-Function CYP2C19 Alleles and Adverse Outcomes in Patients Treated with Clopidogrel
01/17/2011
Tori Socha
In patients presenting with an acute coronary syndrome (ACS), particularly those who are candidates for percutaneous coronary intervention (PCI), clopidogrel has been shown to reduce cardiovascular events. Clopidogrel acts by blocking the...
In patients presenting with an acute coronary syndrome (ACS), particularly those who are candidates for percutaneous coronary intervention (PCI), clopidogrel has been shown to reduce cardiovascular events. Clopidogrel acts by blocking the...
In patients presenting with an...
01/17/2011
First Report Managed Care
Feature
Drug-Eluting Stents as Safe as Bare-Metal Stents and More Effective in Large Coronary Arteries
01/17/2011
Alice Goodman
Chicago—Drug-eluting stents (sirolimus-eluting and everolimus-eluting) were found as safe as a baremetal stent in large arteries of patients with coronary heart disease in the BASKET-PROVE (Basel Stent Kosten-Effektivitäts Trial Prospective...
Chicago—Drug-eluting stents (sirolimus-eluting and everolimus-eluting) were found as safe as a baremetal stent in large arteries of patients with coronary heart disease in the BASKET-PROVE (Basel Stent Kosten-Effektivitäts Trial Prospective...
Chicago—Drug-eluting stents...
01/17/2011
First Report Managed Care
Feature
HeartWare LVAD Achieves Success in Clinical Trial of End-Stage Heart Failure
01/17/2011
Alice Goodman
Chicago—HeartWare (HeartWare International), an investigational left ventricular assist device (LVAD), was successful in treating patients with endstage heart failure as a bridge to transplantation, and it was noninferior compared with other...
Chicago—HeartWare (HeartWare International), an investigational left ventricular assist device (LVAD), was successful in treating patients with endstage heart failure as a bridge to transplantation, and it was noninferior compared with other...
Chicago—HeartWare (HeartWare...
01/17/2011
First Report Managed Care
Feature
STARFlex Closure of PFO Not Superior to Medical Therapy in Preventing Recurrent Stroke
01/17/2011
Alice Goodman
A study presented at the AHA meeting suggests that patent foramen ovale closure using the STARFlex septal repair implantable device is of no benefit in preventing recurrent stroke for the vast majority of patients who have sustained a...
A study presented at the AHA meeting suggests that patent foramen ovale closure using the STARFlex septal repair implantable device is of no benefit in preventing recurrent stroke for the vast majority of patients who have sustained a...
A study presented at the AHA...
01/17/2011
First Report Managed Care
Longer Sleep Duration per Night Associated with Increased Risk of Stroke in Older Women
01/17/2011
Alice Goodman
Research suggests that the risk of stroke is elevated in women who have more—not less—sleep. Women who slept ≥10 hours per night had a 63% increased risk of stroke compared with those who slept <7 hours per night in a substudy of the...
Research suggests that the risk of stroke is elevated in women who have more—not less—sleep. Women who slept ≥10 hours per night had a 63% increased risk of stroke compared with those who slept <7 hours per night in a substudy of the...
Research suggests that the risk...
01/17/2011
First Report Managed Care
Feature
Eplerenone Reduces Deaths and Hospitalizations in Mild Heart Failure
01/17/2011
Alice Goodman
Chicago—Eplerenone added to standard therapy for heart failure (HF) significantly reduced the risk of cardiovascular death or HF in patients with mild HF versus placebo. These findings of the EMPHASIS-HF (Eplerenone in Mild Patients...
Chicago—Eplerenone added to standard therapy for heart failure (HF) significantly reduced the risk of cardiovascular death or HF in patients with mild HF versus placebo. These findings of the EMPHASIS-HF (Eplerenone in Mild Patients...
Chicago—Eplerenone added to...
01/17/2011
First Report Managed Care
Feature
Warfarin Underused in Elderly Patients Undergoing Aortic Valve Replacement
01/17/2011
Alice Goodman
Chicago—Warfarin is used only in a minority of elderly patients after bioprosthetic aortic valve replacement (BVR) surgery, despite the fact that this procedure carries an early risk of thromboembolic events. Elderly patients undergoing BVR...
Chicago—Warfarin is used only in a minority of elderly patients after bioprosthetic aortic valve replacement (BVR) surgery, despite the fact that this procedure carries an early risk of thromboembolic events. Elderly patients undergoing BVR...
Chicago—Warfarin is used only in...
01/17/2011
First Report Managed Care
Feature
ROCKET AF: Rivaroxaban in Atrial Fibrillation
01/17/2011
Alice Goodman
Chicago—Rivaroxaban, an investigational antithrombotic drug, was found to be at least as effective as warfarin in patients with paroxysmal atrial fibrillation (AF), with fewer dangerous side effects, such as intracranial hemorrhage and fatal...
Chicago—Rivaroxaban, an investigational antithrombotic drug, was found to be at least as effective as warfarin in patients with paroxysmal atrial fibrillation (AF), with fewer dangerous side effects, such as intracranial hemorrhage and fatal...
Chicago—Rivaroxaban, an...
01/17/2011
First Report Managed Care
Conference Insider
Excessive Daytime Sleepiness Contributes to Medication Nonadherence
01/17/2011
Alice Goodman
Community-dwelling adults with heart failure (HF) often forget to take their HF medications due to excessive daytime sleepiness, according to a study reported at a poster session during the AHA meeting. 
Community-dwelling adults with heart failure (HF) often forget to take their HF medications due to excessive daytime sleepiness, according to a study reported at a poster session during the AHA meeting. 
Community-dwelling adults with...
01/17/2011
First Report Managed Care
Feature
Prescription Fish Oil Fails to Prevent Recurrent Atrial Fibrillation
01/17/2011
Alice Goodman
Chicago—Fish oil (prescription omega-3 supplements, Lovaza) failed to prevent recurrence of atrial fibrillation (AF) compared with placebo in a randomized controlled trial reported at a late-breaking clinical trials session during the AHA...
Chicago—Fish oil (prescription omega-3 supplements, Lovaza) failed to prevent recurrence of atrial fibrillation (AF) compared with placebo in a randomized controlled trial reported at a late-breaking clinical trials session during the AHA...
Chicago—Fish oil (prescription...
01/17/2011
First Report Managed Care
Conference Insider
Rasagiline Effective in Lowering Adverse Events
01/17/2011
Tim Casey
Prague—In a meta-analysis of clinical trials evaluating the safety profiles of monotherapeutic treatments, researchers found that patients with early Parkinson’s disease (PD) who were treated with rasagiline had a lower risk for adverse...
Prague—In a meta-analysis of clinical trials evaluating the safety profiles of monotherapeutic treatments, researchers found that patients with early Parkinson’s disease (PD) who were treated with rasagiline had a lower risk for adverse...
Prague—In a meta-analysis of...
01/17/2011
First Report Managed Care
Conference Insider
Parkinson’s Disease Patients Suffer During Off-Time
01/17/2011
Tim Casey
A sample of adults ≥30 years of age in the United States with self-reported, doctor-confirmed Parkinson’s disease (PD) found that patients experiencing off-time had worse overall physical and mental well-being than patients who were stable.
A sample of adults ≥30 years of age in the United States with self-reported, doctor-confirmed Parkinson’s disease (PD) found that patients experiencing off-time had worse overall physical and mental well-being than patients who were stable.
A sample of adults ≥30 years of...
01/17/2011
First Report Managed Care
Conference Insider
Economic Burden of Deep Vein Thrombosis
01/17/2011
Tim Casey
In a recent cohort study of 355 patients diagnosed with acute deep vein thrombosis (DVT) at 7 hospitals in Quebec, Canada, researchers found that the average per patient total cost associated with DVT was $5094 (Canadian), with most of the...
In a recent cohort study of 355 patients diagnosed with acute deep vein thrombosis (DVT) at 7 hospitals in Quebec, Canada, researchers found that the average per patient total cost associated with DVT was $5094 (Canadian), with most of the...
In a recent cohort study of 355...
01/17/2011
First Report Managed Care
Feature
Pivotal Phase 2 Study Involving Brentuximab Vedotin in Hodgkin Lymphoma Patients
01/17/2011
Tim Casey
Orlando—A pivotal phase 2, single-arm, multicenter study found that brentuximab vedotin was safe and effective in patients with relapsed or refractory Hodgkin lymphoma who had undergone an autologous stem cell transplant (ASCT). Robert Chen,...
Orlando—A pivotal phase 2, single-arm, multicenter study found that brentuximab vedotin was safe and effective in patients with relapsed or refractory Hodgkin lymphoma who had undergone an autologous stem cell transplant (ASCT). Robert Chen,...
Orlando—A pivotal phase 2,...
01/17/2011
First Report Managed Care
Phase 3 Trial of Pixantrone in Treating Non-Hodgkin Lymphoma Patients
01/17/2011
Tim Casey
Olrando—Compared with other chemotherapy agents, pixantrone proved more effective in treating patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to a randomized, controlled, international, multicenter, open-label, phase 3...
Olrando—Compared with other chemotherapy agents, pixantrone proved more effective in treating patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to a randomized, controlled, international, multicenter, open-label, phase 3...
Olrando—Compared with other...
01/17/2011
First Report Managed Care
Feature
Cost and Burden of Follicular Non-Hodgkin Lymphoma Disease Progression
01/17/2011
Tim Casey
Orlando—A retrospective claims database analysis found disease progression among patients with follicular non-Hodgkin lymphoma (f-NHL) was associated with a $2647 higher per patient per month (PPPM) cost and higher healthcare utilization...
Orlando—A retrospective claims database analysis found disease progression among patients with follicular non-Hodgkin lymphoma (f-NHL) was associated with a $2647 higher per patient per month (PPPM) cost and higher healthcare utilization...
Orlando—A retrospective claims...
01/17/2011
First Report Managed Care
Feature
Patients Taking Defibrotide See Improvement in Complete Response and Day 100 Survival Rates
01/17/2011
Tim Casey
Orlando—A meta-analysis of phase 2 and phase 3 trials found that patients taking defibrotide to treat severe hepatic veno-occlusive disease with multiorgan failure (VOD/MOF) had significantly higher complete response (CR) rates compared with...
Orlando—A meta-analysis of phase 2 and phase 3 trials found that patients taking defibrotide to treat severe hepatic veno-occlusive disease with multiorgan failure (VOD/MOF) had significantly higher complete response (CR) rates compared with...
Orlando—A meta-analysis of phase...
01/17/2011
First Report Managed Care
Conference Insider
Phase 3 Trials Compare Apixaban and Enoxaparin in Treating VTE
01/17/2011
Tim Casey
A pooled analysis of two phase 3 randomized, double-dummy studies found that apixaban was more effective than enoxaparin in preventing venous thromboembolism (VTE) after patients underwent hip or knee replacement surgery. 
A pooled analysis of two phase 3 randomized, double-dummy studies found that apixaban was more effective than enoxaparin in preventing venous thromboembolism (VTE) after patients underwent hip or knee replacement surgery. 
A pooled analysis of two phase 3...
01/17/2011
First Report Managed Care
Feature
Nilotinib and Imatinib Mesylate in Patients with Ph+ CML
01/17/2011
Tim Casey
Orlando—According to 24-month follow-up data from a phase 3, randomized, open-label, multicenter trial, 150-mg capsules of nilotinib had better results than imatinib mesylate tablets when treating adult patients with chronic phase, newly...
Orlando—According to 24-month follow-up data from a phase 3, randomized, open-label, multicenter trial, 150-mg capsules of nilotinib had better results than imatinib mesylate tablets when treating adult patients with chronic phase, newly...
Orlando—According to 24-month...
01/17/2011
First Report Managed Care
Feature
Rituximab Effective in Patients with Asymptomatic, Advanced Stage Follicular Lymphoma
01/17/2011
Tim Casey
Orlando—In an international, multicenter, randomized phase 3 trial of 462 patients with previously untreated asymptomatic, advanced stage follicular lymphoma, researchers concluded that rituximab significantly improved time to initiation of...
Orlando—In an international, multicenter, randomized phase 3 trial of 462 patients with previously untreated asymptomatic, advanced stage follicular lymphoma, researchers concluded that rituximab significantly improved time to initiation of...
Orlando—In an international,...
01/17/2011
First Report Managed Care
Feature
Combining Novel Agents to Treat Lymphoma
01/17/2011
Tim Casey
Orlando—In the past few years, the US Food and Drug Administration has approved several therapies to treat lymphoma, including rituximab, tositumomab, bortezomib, vorinostat, bendamustine, and pralatrexate. Recently, medical professionals...
Orlando—In the past few years, the US Food and Drug Administration has approved several therapies to treat lymphoma, including rituximab, tositumomab, bortezomib, vorinostat, bendamustine, and pralatrexate. Recently, medical professionals...
Orlando—In the past few years,...
01/17/2011
First Report Managed Care
News Connection
States Gain Power to Review Health Premium Increases
01/17/2011
Tim Casey
To hold insurers accountable when implementing rate increases and help consumers concerned with rising healthcare costs, the Patient Protection and Affordable Care Act (HR 3590) granted states increased authority to review rate increases.
To hold insurers accountable when implementing rate increases and help consumers concerned with rising healthcare costs, the Patient Protection and Affordable Care Act (HR 3590) granted states increased authority to review rate increases.
To hold insurers accountable...
01/17/2011
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

January 2011 Volume 8 Issue 1

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use